Post-ASH CLL highlights: BTK inhibitors & degraders, bispecific antibodies, & more!

VJHemOnc recently attended the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA, where we gained expert insights into cutting-edge research in hematological malignancies. This podcast series will cover highlights in a variety of disease areas. Today's episode focuses on chronic lymphocytic leukemia (CLL). 

You will hear from experts Jeff Sharman, MD, Willamette Valley Cancer Institute, Eugene, OR, Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, Nirav Niranjan Shah, MD, Medical College of Wisconsin, Milwaukee, WI, and Chan Cheah, MBBS, FRACP, FRCPA, DMSc, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia. They discuss key updates on the use of BTK inhibitors in CLL, including the BRUIN CLL-321 (NCT04666038) and AMPLIFY (NCT03836261) trials, as well as the BTK degraders NX-2127 and NX-5948. They then go on to speak about novel approaches being explored, including treatment with the bispecific antibody epcoritamab in the EPCORE-CLL1 (NCT04623541) trial, and the use of sonrotoclax in the BGB-11417-101 (NCT04277637) trial.